CA2098101A1 - A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis - Google Patents

A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis

Info

Publication number
CA2098101A1
CA2098101A1 CA002098101A CA2098101A CA2098101A1 CA 2098101 A1 CA2098101 A1 CA 2098101A1 CA 002098101 A CA002098101 A CA 002098101A CA 2098101 A CA2098101 A CA 2098101A CA 2098101 A1 CA2098101 A1 CA 2098101A1
Authority
CA
Canada
Prior art keywords
cholesterol
vaccine according
delivery vehicle
vaccine
phosphatidyl choline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002098101A
Other languages
English (en)
French (fr)
Inventor
Carl R. Alving
Glenn M. Swartz, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2098101A1 publication Critical patent/CA2098101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
CA002098101A 1990-12-10 1991-12-10 A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis Abandoned CA2098101A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62495790A 1990-12-10 1990-12-10
US624,957 1990-12-10

Publications (1)

Publication Number Publication Date
CA2098101A1 true CA2098101A1 (en) 1992-06-10

Family

ID=24504021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098101A Abandoned CA2098101A1 (en) 1990-12-10 1991-12-10 A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis

Country Status (5)

Country Link
EP (1) EP0562020A4 (ja)
JP (1) JP3183665B2 (ja)
AU (1) AU666473B2 (ja)
CA (1) CA2098101A1 (ja)
WO (1) WO1992010203A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
DK0831881T3 (da) 1995-06-06 2003-07-07 Avant Immunotherapeutics Inc CETP til forøgelse af HDL-cholesterolniveau
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6846808B1 (en) 1996-05-01 2005-01-25 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
CA2562550C (en) 2004-04-15 2013-09-24 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
JP6277125B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリンに対する新規抗体
JP6277126B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR704M (ja) * 1960-10-10 1961-07-31
US4885256A (en) * 1986-06-17 1989-12-05 The United States Of America As Represented By The United States Army Monoclonal antibodies to cholesterol and methods
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
CA2094588A1 (en) * 1990-10-22 1992-04-23 Carl R. Alving Lipid a composition as immunogenic agents to prevent or treat gram-negative bacterial infections

Also Published As

Publication number Publication date
JP3183665B2 (ja) 2001-07-09
WO1992010203A1 (en) 1992-06-25
EP0562020A1 (en) 1993-09-29
AU666473B2 (en) 1996-02-15
EP0562020A4 (en) 1993-11-18
JPH06505714A (ja) 1994-06-30
AU9155691A (en) 1992-07-08

Similar Documents

Publication Publication Date Title
Dinu et al. Fequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE
US6803042B2 (en) Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
EP0762875B1 (en) Microparticle delivery system
Kinsky et al. Immunological properties of model membranes
Alving et al. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation
US6093406A (en) Vaccine for induction of immunity to malaria
AU2005284133A1 (en) Treatment of atherosclerosis
Facer et al. High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria
CA2098101A1 (en) A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
US5013555A (en) Agent for desensitizing man and/or animals against an allergen
Allaoui-Attarki et al. Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D, L-lactide-co-glycolide) microspheres
US5888519A (en) Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
Erridge et al. The biological activity of a liposomal complete core lipopolysaccharide vaccine
US6224902B1 (en) Vaccines against sterols
Reed et al. Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii
WO1999052547A1 (en) Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
Glenn et al. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A
US7074407B1 (en) Method for increasing HDL cholesterol level
US20070122419A1 (en) Methods and compositions for treating atherosclerosis
US20020018808A1 (en) Vaccines against sterols
AU667028B2 (en) Lipid A composition as immunogenic agents to prevent or treat gram-negative bacterial infections
WO1994014454A1 (en) Vaccines against sterols
EP1282430B1 (en) Lipids for stimulation of immune response
Correa et al. Adjuvant effect of liposomes in the autoimmune response to rat male accessory glands
Pham et al. Oral feeding of renal tubular antigen abrogates interstitial nephritis and renal failure in Brown Norway rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead